RAT Race Begins: FDA Accepting Regenerative Advanced Therapy Designation Requests
Executive Summary
As part of a flurry of actions in the waning days of the Obama Administration, FDA formally announced a process for requesting the new “Regenerative Advanced Therapy” designation. Much like the early days of “Breakthrough,” the standards are uncertain for now.
You may also be interested in...
Regenerative Medicine Clinical Trials: US FDA Supports Studies Comparing Multiple Agents
Draft guidance suggests comparing therapies for a rare disease to each other and active control, offers examples of novel efficacy endpoints and what therapies may qualify for breakthrough and RMAT designations.
CAR-T Cancer Drugs Front And Center At ARM Investor Day
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.